Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion

Clinical Ophthalmology

Volumn 10, Issue , 2016, Pages 939-946

  Sivaprasad, Sobha ^a   Oyetunde, Sesan ^b  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b ALLERGAN PLC   (United States)

Author keywords

Burden; DME; Intravitreal; Quality of life; Questionnaire; Retina; RVO

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; RANIBIZUMAB;

ADULT; AGED; ANXIETY; ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; FEMALE; HOSPITAL MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; QUALITY OF LIFE; QUESTIONNAIRE; RETINA VEIN OCCLUSION; TREATMENT OUTCOME;

EID: 84973594554     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S100168     Document Type: Article

References (45)

1. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-564.
2. Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol. 2012;96:345-349.
3. International Diabetes Federation [webpage on the Internet]. IDF Diabetes Atlas. 6th ed; 2013 [cited May, 2015]. Available from: http://www.idf.org/diabetesatlas. Accessed March 8, 2016.
4. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular oedema. Curr Diab Rep. 2012;12:346-354.
5. Royal College of Ophthalmologists. Guidelines for Retinal Vein Occlusion. London: Royal College of Ophthalmologists; 2015.
6. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133-141.
7. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis and treatment modalities. Curr Eye Res. 2008;33:111-131.
8. Laouri M, Chen E, Looman M, Gallagher M. The burden of disease of retinal vein occlusion: review of the literature. Eye. 2011;25:981-988.
9. US Census information [webpage on the Internet]. International Data Base [cited May, 2015]. Available from: http://www.census.gov/population/international/data/idb/informationGateway.php. Accessed March 8, 2016.
10. Hariprasad SM, Mieler WF, Grassi M, Green JL, Jager RD, Miller L. Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol. 2008;92:89-92.
11. Klein R, Moss SE, Klein BE, Gutierrez P, Mangione CM. The NEI-VFQ-25 in people with long term type 1 diabetes mellitus. Arch Ophthalmol. 2001;119:733-740.
12. Christ SL, Zheng DD, Swenor BK, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Longitudinal relationships among visual acuity, daily functional status, and mortality: the Salisbury Eye Evaluation Study. JAMA Ophthalmol. 2014;132:1400-1406.
13. Weinberg DV, Seddon JM. Venous occlusive diseases of the retina. In: Albert DM, Jakobiec FA, editors. Principles and Practice of Ophthalmology. Vol. 2. Philadelphia: W.B. Saunders Company; 1994:735-746.
14. Johnson MW. Etiology and treatment of macular oedema. Am J Ophthalmol. 2009;147:11-21.
15. +. Novartis Pharmaceuticals UK, Ltd; 2016. Available from https://www.medicines.org.uk/emc/medicine/19409. Accessed April 28, 2016.
16. +. Bayer plc; 2016. Available from https://www.medicines.org.uk/emc/medicine/27224. Accessed April 28, 2016.
17. +. Allergen Ltd; 2015. Available from https://www.medicines.org.uk/emc/medicine/23422. Accessed April 28, 2016.
18. +. Alimera Sciences; 2015. Available from https://www.medicines.org.uk/emc/medicine/27636. Accessed April 28, 2016.
19. Lee LJ, Yu AP, Cahill KE, et al. Direct and indirect costs among employees with diabetic retinopathy in the United States. Curr Med Res Opin. 2008;24:1549-1559.
20. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010;26:1587-1596.
21. Access Economics [webpage on the Internet]. Future sight loss in the UK (1): the economic impact of partial sight and blindness in the UK adult population. Full report. Report prepared for RNIB; 2009 [cited May, 2015]. Available from: www.rnib.org.uk/aboutus/Research/reports/2009andearlier/FSUK_Report.pdf. Accessed March 8, 2016.
22. Appiah A [webpage on the Internet]. Retinal Physician; 2013 [cited May, 2015]. Available from: http://www.iridex.com/Portals/0/dme/Appiah-532-MPLT-Retinal-Physician-2013.pdf. Accessed March 8, 2016.
23. Fu AZ, Qiu Y, Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Curr Med Res Opin. 2009;25:1413-1420.
24. Chen X, Seth RK, Rao VS, Huang JJ, Adelman RA. Effects of music therapy on intravitreal injections: a randomized clinical trial. J Ocul Pharmacol Ther. 2012;28:414-419.
25. AADE Guide Diabetes Self-Management. A Guide to Encouraging Your Patients to Speak about Their Injections. Chicago, IL: AADE; 2010.
26. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789-801.
27. Do DV, Nguyen QD, Boyer D, et al; da Vinci Study Group. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119:1658-1665.
28. Gillies MC, Lim LL, Campain A, et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121:2473-2481.
29. Elsing SH, Shidhaye N, Deramo VA. Vision-related quality of life in patients with branch retinal vein occlusion (RVO) using the National Eye Institute Visual Functioning Questionnaire-25 (VFQ-25). Invest Ophthalmol Vis Sci. 2001;42:S236. [Abstract 1273-B586].
30. Awdeh RM, Elsing SH, Deramo VA, Stinnett S, Lee PP, Fekrat S. Vision-related quality of life in persons with branch retinal vein occlusion (BRVO) using the 25-item NEI Visual Function Questionnaire. Br J Ophthalmol. 2010;94:319-323.
31. Deramo VA, Cox TA, Syed AB, Lee PP, Fekrat S. Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2003;121:1297-1302.
32. Fenwick EK, Xie J, Ratcliffe J, et al. The impact of diabetic retinopathy and diabetic macular edema on health-related quality of life in type 1 and type 2 diabetes. Invest Ophthalmol Vis Sci. 2012;53:677-684.
33. Campbell J, Cole AL, Almony A, et al. Real World Vision Outcomes in DMO Treated with Anti-VEGF Injections - An Analysis of EMR Data From a Large Health System 2014. Abstract 3065 Presented at: ARVO 2014; Orlando, FL.
34. Kiss S, Liu Y, Brown J, et al. Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. Clin Ophthalmol. 2014;8:1611-1621.
35. Brown DM, Nguyen QD, Marcus DM, et al; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013-2022.
36. Boyer DS, Yoon YH, Belfort R Jr, et al; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904-1914.
37. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615-625.
38. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121:2247-2254.
39. Kanavos P, van den Aardweg S, Schurer W [webpage on the Internet]. Diabetes expenditure, burden of disease and management in 5 EU countries [cited May, 2015]. Available from: http://www.lse.ac.uk/LSEHealthAndSocialCare/research/LSEHealth/MTRG/LSEDiabetesReport26Jan2012.pdf. Accessed March 8, 2016.
40. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care. 2006;29:725-731.
41. Vijan S, Hayward RA, Ronis DL, Hofer TP. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med. 2005;20:479-482.
42. RNIB [webpage on the Internet]. Saving Money, Losing Sight. RNIB Campaign Report; 2013 [cited May, 2015]. Available from: http://www.rnib.org.uk/sites/default/files/Saving%20money%20losing%20sight%20Campaign%20report_0.pdf. Accessed March 8, 2016.
43. Lafuma A, Brézin A, Lopatriello S, et al. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK. Pharmacoeconomics. 2006;24:193-205.
44. Busuttil S. Vision for the future. Parliament Mag. 2011;320:23.
45. Fekrat S, Shea AM, Hammill BG, et al. Resource use and costs of branch and central retinal vein occlusion in the elderly. Curr Med Res Opin. 2010;26:223-230.